IPP Bureau
Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy
By IPP Bureau - February 24, 2026
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
UK pours £20 million into cutting?edge tech to tackle drug & alcohol addiction
By IPP Bureau - February 24, 2026
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy
By IPP Bureau - February 24, 2026
If approved, DTX401 would be the first treatment to address the disease at its root cause
AIM ImmunoTech advances Phase 2 pancreatic cancer trial with Ampligen and Imfinzi
By IPP Bureau - February 24, 2026
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
Novo Nordisk’s "Triple G" drug UBT251 triggers nearly 20% weight loss in 24 weeks
By IPP Bureau - February 24, 2026
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Artemis Medicare to manage 650-bed VIMHANS Hospital in Rs. 520 South Delhi expansion
By IPP Bureau - February 23, 2026
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL
By IPP Bureau - February 23, 2026
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
CARE Hospitals positions workforce health as a strategic business imperative at HR Conclave 2026
By IPP Bureau - February 23, 2026
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar
By IPP Bureau - February 23, 2026
BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data
Surya Brasil eyes India expansion after 30% US growth
By IPP Bureau - February 23, 2026
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
PharmEasy integrates with Samsung Health to streamline digital healthcare
By IPP Bureau - February 23, 2026
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
BioVersys’ novel TB drug shows promising results in Phase 2a Trial
By IPP Bureau - February 23, 2026
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal
By IPP Bureau - February 23, 2026
Bavarian Nordic bags $22.5M Canadian vaccine order
By IPP Bureau - February 23, 2026
The order will cover the manufacturing of bulk vaccine in 2026
Siegfried delivers strong 2025 performance, bolsters US expansion
By IPP Bureau - February 23, 2026
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
